DEA Temporarily Schedules Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 as Schedule I Substances
More From This Agency
- Justice Department Establishes National Fraud Enforcement Division August 18, 2026
- DEA Proposes Moving Suvorexant, Lemborexant, and Daridorexant from Schedule IV to Schedule V August 16, 2026
Plain-English Summary
The rule permanently adds mitragynine pseudoindoxyl, MGM‑15, and MGM‑16, plus any of their isomers, esters, ethers, and salts, to Schedule I. It applies the full suite of regulatory controls, civil penalties, and criminal sanctions that already exist for Schedule I drugs. The order covers all activities including manufacturing, distribution, import, export, research, instructional use, and chemical analysis. The DEA justified the action as necessary to avoid an imminent hazard to public safety.
Current Status
This is a final rule that took effect immediately upon publication.
What This Means
Anyone who manufactures, distributes, imports, exports, or possesses mitragynine pseudoindoxyl, MGM‑15, or MGM‑16—along with any of their isomers, esters, ethers, or salts—must now comply with Schedule I requirements. The DEA’s order automatically treats these substances as having no accepted medical use and a high potential for abuse. All associated civil and criminal penalties for Schedule I violations now apply to these chemicals. Researchers and laboratories must obtain a Schedule I registration or cease work with the substances. The language of the abstract explicitly extends the scheduling to any possible analogues, so even undiscovered derivatives are covered.
Who Is Affected
Pharmaceutical manufacturers developing novel analgesics that might include 7‑hydroxymitragynine scaffolds are directly impacted. Academic and private research labs conducting chemical analysis or pharmacology studies on these compounds now need Schedule I registration. Law‑enforcement and customs agencies will enforce the new controls on import and export. Companies that previously handled these substances under lower schedules must update compliance programs.
Background
The DEA acted under the Controlled Substances Act after finding that the three compounds pose an imminent risk to public safety, likely due to their potency as opioid analogues. Prior to this order, the substances were not listed, creating a regulatory gap as they appeared in emerging illicit markets. The temporary scheduling fills that gap while the agency evaluates longer‑term classification. This action follows the statutory authority to place substances in Schedule I when a hazard is imminent.
Arguments For
Placing these potent opioid analogues in Schedule I prevents their diversion into the illicit drug supply, protecting public health. The order’s breadth—including all isomers, esters, ethers, and salts—closes loopholes that traffickers could exploit to evade control.
Arguments Against
The abstract does not indicate any substantive controversy, and no organized opposition is cited. Potential concerns would revolve around added regulatory burden for legitimate scientific research, but the rule itself provides no indication of significant pushback.
Economic Considerations
Because the abstract contains no official cost estimate, any economic analysis is speculative. Companies will incur compliance costs for registration, record‑keeping, and potential redesign of research protocols. Law‑enforcement agencies may need additional resources to monitor and enforce the new schedule. Conversely, reduced availability of these potent opioids could lower societal costs associated with addiction and overdose, though quantifying that effect is uncertain.
Sections beyond the plain-English summary are AI-synthesized analysis based on the sourced Federal Register filing, read, edited where needed, and approved by a human editor before publication. Full methodology: Editorial & Methodology.
← All Records